Recursion Pharmaceuticals (RXRX) Acquisitions (2023 - 2024)
Recursion Pharmaceuticals (RXRX) posted Acquisitions of -$277.1 million for Q4 2024, down 390387.32% on a QoQ basis from $71000.0 in Q4 2023, and down 390387.32% year-over-year from N/an in Q1 2024.
Recursion Pharmaceuticals (RXRX) Acquisitions (2023 - 2024) Analysis & Trends
Recursion Pharmaceuticals' Acquisitions history runs 2 years deep, the most recent figure standing at -$277.1 million for Q4 2024.
- Quarterly Acquisitions fell 390387.32% year-over-year to -$277.1 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$277.0 million (down 390287.32% YoY) and the FY2024 annual result came in at -$277.1 million, down 14927.33% from the prior year.
- Acquisitions was -$277.1 million for Q4 2024 at Recursion Pharmaceuticals, down from $71000.0 in the prior quarter.
- Across five years, Acquisitions topped out at $71000.0 in Q4 2023 and bottomed at -$277.1 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acquisitions (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Recursion Pharmaceuticals | 1.57 Bn | 912.05 Mn | -6.02 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -277.10 Mn |
| Dec 31, 2023 | 71,000.00 |